Chugai Pharmaceutical Co., Ltd.

Tokyo Stock Exchange 4519.T

Chugai Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 8.84

Chugai Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) is 8.84 on January 14, 2025, a 3.95% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Chugai Pharmaceutical Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 10.78 on September 27, 2024, which is 21.92% above the current Price to Sales Ratio (P/S).
Chugai Pharmaceutical Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 6.21 on May 29, 2024, which is -29.80% below the current Price to Sales Ratio (P/S).
Chugai Pharmaceutical Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 8.43.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Tokyo Stock Exchange: 4519.T

Chugai Pharmaceutical Co., Ltd.

CEO	Dr. Osamu Okuda
IPO Date	Jan. 4, 2000
Location	Japan
Headquarters	Nihonbashi Mitsui Tower
Employees	7,604
Sector	Health Care
Industries Pharmaceuticals Cosmetics

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Key trends

Past 5 years